Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
July 10th, 2024
Donanemab Approved for Alzheimer's Disease; Positive News for Cogstate
Read More
July 10th, 2024
Radiopharm to Raise $70 Million Following Transformational Lantheus Deal
Read More
June 13th, 2024
Neuren Pharmaceuticals: Positive Phase II Results in Second Study with NNZ-2591
Read More
June 13th, 2024
Anteris Technologies to Seek Nasdaq Listing Ahead of Registration Study
Read More
June 12th, 2024
Second Licensing Deal for Dimerix; Share Price Up 65%
Read More
May 19th, 2024
Blinklab Partners with Autism Foundation for Pre-Registration Study
Read More
April 19th, 2024
IPO Preview – Blinklab
Read More
January 4th, 2024
Top Six Picks for 2024 (Dimerix; ASX = DXB)
Read More
January 4th, 2024
Impressive Results from Neuren's NNZ-2591 Phase II Clinical Trial in Phelan- McDermid Syndrome
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Clinuvel)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Dimerix)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Imugene)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Neuren)
Read More
November 20th, 2023
Neuren Completes First of Four Phase II Studies
Read More
November 20th, 2023
Adalta Finalises Data for Licensing with Lead Compound AD214
Read More
November 20th, 2023
Clinuvel Pharmaceuticals - Core Growth Focus Ahead
Read More
November 20th, 2023
First Results for Imugene's Oncolytic Virus CF33
Read More
November 3rd, 2023
Chimeric Therapeutics - Four Phase Ib Studies in 2024 Ahead of Partnering Deals
Read More
November 3rd, 2023
Anteris Technologies Secures $40 Million in Capital Raise to Prepare for Pivotal Study
Read More
November 3rd, 2023
Immuron Achieves Record Travelan Sales in September Quarter
Read More
Pages
1
2
3
4
5
6
7
8
9
